ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Coronavirus

US grants $265m for Fujifilm's COVID-19 vaccine project

Assistance comes as Trump administration pushes ahead with Operation Warp Speed

U.S. President Donald Trump said that the U.S. government will award $265 million to Fujifilm Holdings to help expand vaccine production to combat the coronavirus pandemic. He visited the Bioprocess Innovation Center at Fujifilm Diosynth Biotechnologies in Morrisville, North Carolina on July 27.   © AP

WASHINGTON -- The U.S. government announced on Monday that it will award $265 million to Fujifilm Holdings to help expand vaccine production to combat the coronavirus pandemic.

President Donald Trump made the announcement when he visited the Bioprocess Innovation Center at Fujifilm Diosynth Biotechnologies in Morrisville, North Carolina.

According to the Japanese company, it will invest to increase vaccine manufacturing capacity at its facility in Texas by autumn before starting mass production in early 2021.

Trump said the funding will "dramatically expand their vaccine manufacturing capacity."

Diosynth Biotechnologies, which Fujifilm acquired in 2011 and is also invested in by Mitsubishi Corporation, has a contract for the manufacturing of the drug substance for Novavax, a developer of coronavirus vaccines.

Fujifilm Diosynth Biotechnologies CEO Martin Meeson, right, speaks as President Donald Trump wears a face mask as he participates in a tour of Bioprocess Innovation Center at Fujifilm Diosynth Biotechnologies in Morrisville, U.S. on July 27.    © AP

According to a contract with the U.S. Department of Health through December 2021, the government's funding can be used to increase the production of vaccines at government-supported developers such as Novavax.

The funding is part of Operation Warp Speed, the Trump administration's effort to accelerate vaccine development that aims to start supplying 300 million doses, a number nearly equivalent to the country's total population.

In addition to Novavax, the U.S. government has awarded financial support to other vaccine developers including Pfizer. If the safety and efficacy of vaccines can be confirmed in clinical trials, the administration will support capital investment by their developers.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media